
## Christopher J Earley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9348818/publications.pdf Version: 2024-02-01



| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal<br>Terminals: Implications for Restless Legs Syndrome. Molecules, 2022, 27, 1489.                                 | 3.8 | 11        |
| 2  | RestEaze: An Emerging Technology to Characterize Leg Movements During Sleep. Journal of Medical<br>Devices, Transactions of the ASME, 2022, 16, .  | 0.7 | 2         |
| 3  | Brain-iron deficiency models of restless legs syndrome. Experimental Neurology, 2022, 356, 114158.   | 4.1 | 16        |
| 4  | Pilot study: can machine learning analyses of movement discriminate between leg movements in sleep (LMS) with vs. without cortical arousals?. Sleep and Breathing, 2021, 25, 373-379.                                | 1.7 | 4         |
| 5  | Developing a biomarker for restless leg syndrome using genome wide DNA methylation data. Sleep<br>Medicine, 2021, 78, 120-127.   | 1.6 | 4         |
| 6  | Akathisia and Restless Legs Syndrome. Sleep Medicine Clinics, 2021, 16, 249-267.   | 2.6 | 9         |
| 7  | The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings, 2021, 96, 1921-1937.  | 3.0 | 67        |
| 8  | We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless<br>legs syndrome screening instruments. Sleep Medicine Reviews, 2021, 58, 101461.                                | 8.5 | 22        |
| 9  | Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. Sleep Medicine, 2021, 84, 179-186.   | 1.6 | 7         |
| 10 | The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients. Frontiers in<br>Neurology, 2021, 12, 786408.  | 2.4 | 2         |
| 11 | Moderate to severe but not mild RLS is associated with greater sleep-related sympathetic autonomic activation than healthy adults without RLS. Sleep Medicine, 2020, 68, 89-95.                                      | 1.6 | 15        |
| 12 | Resting-state connectivity and the effects of treatment in restless legs syndrome. Sleep Medicine, 2020, 67, 33-38.  | 1.6 | 9         |
| 13 | Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. Sleep Medicine, 2020, 71, 141-148.                 | 1.6 | 15        |
| 14 | Developing a behavioral model of Restless Legs Syndrome utilizing mice with natural variances in ventral midbrain iron. Sleep Medicine, 2020, 71, 135-140.   | 1.6 | 4         |
| 15 | Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. Fluids and Barriers of the CNS, 2020, 17, 28.   | 5.0 | 6         |
| 16 | New Insights into the Neurobiology of Restless Legs Syndrome. Neuroscientist, 2019, 25, 113-125.   | 3.5 | 85        |
| 17 | Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome.<br>Sleep, 2019, 42, .   | 1.1 | 13        |
| 18 | Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Medicine, 2018, 41, 27-44 | 1.6 | 228       |

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. Mayo Clinic Proceedings, 2018, 93, 59-67.   | 3.0  | 47        |
| 20 | Diurnal variation of default mode network in patients with restless legs syndrome. Sleep Medicine, 2018, 41, 1-8.   | 1.6  | 29        |
| 21 | Efficacy of ferric carboxymaltose (FCM) 500Âmg dose for the treatment of Restless Legs Syndrome.<br>Sleep Medicine, 2018, 42, 7-12.   | 1.6  | 16        |
| 22 | A direct interaction between two Restless Legs Syndrome predisposing genes: MEIS1 and SKOR1.<br>Scientific Reports, 2018, 8, 12173.   | 3.3  | 23        |
| 23 | Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period.<br>Sleep Medicine, 2018, 52, 80-87.  | 1.6  | 4         |
| 24 | Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Medicine, 2017, 31, 71-77. | 1.6  | 46        |
| 25 | Intervening Leg Movements Disrupt PLMS Sequences. Sleep, 2017, 40, .  | 1.1  | 3         |
| 26 | Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurology, The, 2017, 16, 898-907.                             | 10.2 | 191       |
| 27 | Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis.<br>Sleep Medicine, 2017, 38, 44-49.  | 1.6  | 4         |
| 28 | In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. Sleep Medicine, 2017, 31, 86-92.   | 1.6  | 34        |
| 29 | Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Annals of Neurology, 2017, 82, 951-960.   | 5.3  | 52        |
| 30 | Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. Frontiers in Neuroscience, 2017, 11, 722.  | 2.8  | 64        |
| 31 | Inter-movement interval as a primary stable measure of periodic limb movements of sleep. Sleep<br>Medicine, 2016, 17, 138-143.  | 1.6  | 8         |
| 32 | Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome.<br>Neuropharmacology, 2016, 111, 160-168.   | 4.1  | 45        |
| 33 | Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep<br>Medicine, 2016, 25, 16-23.   | 1.6  | 46        |
| 34 | Defining morphology of periodic leg movements in sleep: an evidence-based definition of a minimum window of sustained activity. Sleep and Breathing, 2016, 20, 1293-1299.   | 1.7  | 5         |
| 35 | Default mode network disturbances in restless legs syndrome/Willis–Ekbom disease. Sleep Medicine,<br>2016, 23, 6-11.  | 1.6  | 27        |
| 36 | Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. Sleep Medicine, 2016, 22, 75-82.  | 1.6  | 70        |

| #  | Article   | IF         | CITATIONS   |
|----|---|------------|-------------|
| 37 | Response to the letter "Characterization of the painful restless legs syndrome― Sleep Medicine, 2015,<br>16, 1448.  | 1.6        | 1           |
| 38 | A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome. Medical Devices: Evidence and Research, 2015, 8, 341.  | 0.8        | 9           |
| 39 | MATPLM1, A MATLAB script for scoring of periodic limb movements: preliminary validation with visual scoring. Sleep Medicine, 2015, 16, 1541-1549.   | 1.6        | 18          |
| 40 | Co-registration of magnetic resonance spectroscopy and transcranial magnetic stimulation. Journal of Neuroscience Methods, 2015, 242, 52-57.  | 2.5        | 9           |
| 41 | Response to "Characterization of the painful restless legs syndrome― Sleep Medicine, 2015, 16, 898.   | 1.6        | 0           |
| 42 | Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. Sleep Medicine, 2015, 16, 775-778.   | 1.6        | 33          |
| 43 | Gray matter alteration in patients with restless legs syndrome: a voxel-based morphometry study.<br>Clinical Imaging, 2015, 39, 20-25.  | 1.5        | 36          |
| 44 | Altered white matter integrity in primary restless legs syndrome patients: diffusion tensor imaging study. Neurological Research, 2014, 36, 769-774.  | 1.3        | 28          |
| 45 | Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome<br>(Willis–Ekbom disease). Sleep Medicine, 2014, 15, 1473-1476.  | 1.6        | 55          |
| 46 | Functional connectivity alternation of the thalamus in restless legs syndrome patients during the<br>asymptomatic period: a resting-state connectivity study using functional magnetic resonance imaging.<br>Sleep Medicine, 2014, 15, 289-294.               | 1.6        | 63          |
| 47 | Low brain iron effects and reversibility on striatal dopamine dynamics. Experimental Neurology, 2014, 261, 462-468.   | 4.1        | 52          |
| 48 | Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis–Ekbom) Tj ETQqC  | 0.0 rgBT / | Oyerlock 10 |
| 49 | Latest Guidelines and Advances for Treatment of Restless Legs Syndrome. Journal of Clinical Psychiatry, 2014, 75, e08.  | 2.2        | 8           |
| 50 | Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease. Fluids and Barriers of the CNS, 2013, 10, 20.   | 5.0        | 32          |
| 51 | The long-term treatment of restless legs syndrome/Willis–Ekbom disease: evidence-based guidelines<br>and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome<br>Study Group. Sleep Medicine, 2013, 14, 675-684. | 1.6        | 260         |
| 52 | Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Medicine, 2013,<br>14, 274-277.   | 1.6        | 54          |
| 53 | Willis-Ekbom Disease Foundation Revised Consensus Statement on the Management of Restless Legs<br>Syndrome. Mayo Clinic Proceedings, 2013, 88, 977-986.   | 3.0        | 131         |

<sup>54</sup>The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. American<br/>Journal of Hematology, 2013, 88, 261-264.4.1189

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Thalamic glutamate/glutamine in restless legs syndrome. Neurology, 2013, 80, 2028-2034.  | 1.1  | 156       |
| 56 | Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. Sleep, 2013, 36, 51-57.  | 1.1  | 93        |
| 57 | Association of Restless Legs Syndrome Variants in Korean Patients with Restless Legs Syndrome. Sleep, 2013, 36, 1787-1791.   | 1.1  | 27        |
| 58 | Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. , 2013, , 179-197.   |      | 1         |
| 59 | Systems genetic analysis of multivariate response to iron deficiency in mice. American Journal of<br>Physiology - Regulatory Integrative and Comparative Physiology, 2012, 302, R1282-R1296.   | 1.8  | 24        |
| 60 | Dissociative Changes in the B <sub>max</sub> and K <sub>D</sub> of Dopamine<br>D <sub>2</sub> /D <sub>3</sub> Receptors with Aging Observed in Functional Subdivisions of the<br>Striatum: A Revisit with an Improved Data Analysis Method. Journal of Nuclear Medicine, 2012, 53,<br>805-812. | 5.0  | 17        |
| 61 | Systems genetic analysis of the effects of iron deficiency in mouse brain. Neurogenetics, 2012, 13, 147-157.   | 1.4  | 36        |
| 62 | Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome.<br>Sleep Medicine, 2011, 12, 614-619.  | 1.6  | 72        |
| 63 | A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless<br>legs syndrome. Sleep Medicine, 2011, 12, 440-444.  | 1.6  | 159       |
| 64 | Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. Sleep Medicine, 2011, 12, 906-913.  | 1.6  | 126       |
| 65 | The Dopamine Transporter is Decreased in the Striatum of Subjects with Restless Legs Syndrome. Sleep, 2011, 34, 341-347.   | 1.1  | 126       |
| 66 | Another dopamine agonist for treatment of restless legs syndrome. Lancet Neurology, The, 2011, 10,<br>675-677.   | 10.2 | 1         |
| 67 | Profile of altered brain iron acquisition in restless legs syndrome. Brain, 2011, 134, 959-968.  | 7.6  | 203       |
| 68 | Restless legs syndrome and periodic leg movements in sleep. Handbook of Clinical Neurology / Edited<br>By P J Vinken and G W Bruyn, 2011, 99, 913-948.   | 1.8  | 21        |
| 69 | Pregnancy accounts for most of the gender difference in prevalence of familial RLS. Sleep Medicine, 2010, 11, 310-313.   | 1.6  | 90        |
| 70 | Restless legs syndrome: Understanding its consequences and the need for better treatment. Sleep<br>Medicine, 2010, 11, 807-815.  | 1.6  | 165       |
| 71 | Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats. Experimental Neurology, 2010, 224, 292-298.  | 4.1  | 27        |
| 72 | Diurnal cycle influences peripheral and brain iron levels in mice. Journal of Applied Physiology, 2009,<br>106, 187-193.   | 2.5  | 38        |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain, 2009, 132, 2403-2412.  | 7.6 | 299       |
| 74 | Iron Dysregulation in Restless Legs Syndrome. , 2009, , 61-68.   |     | 1         |
| 75 | Diminished iron concentrations increase adenosine A2A receptor levels in mouse striatum and cultured human neuroblastoma cells. Experimental Neurology, 2009, 215, 236-242.  | 4.1 | 22        |
| 76 | Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Medicine, 2009, 10, 123-128.  | 1.6 | 85        |
| 77 | A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs<br>syndrome. Sleep Medicine, 2009, 10, 206-211.  | 1.6 | 114       |
| 78 | RLS and blood donation. Sleep Medicine, 2009, 10, 844-849.   | 1.6 | 24        |
| 79 | The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimicsâ€). Sleep Medicine, 2009, 10, 976-981.   | 1.6 | 246       |
| 80 | The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Medicine, 2009, 10, 1155-1157.   | 1.6 | 75        |
| 81 | Iron Deficiency Alters the Dayâ€Night Variation in Monoamine Levels in Mice. Chronobiology<br>International, 2009, 26, 447-463.  | 2.0 | 31        |
| 82 | Mitochondrial Ferritin in the Substantia Nigra in Restless Legs Syndrome. Journal of Neuropathology<br>and Experimental Neurology, 2009, 68, 1193-1199.  | 1.7 | 68        |
| 83 | Neuroimaging in Restless Legs Syndrome. , 2009, , 78-82.   |     | 3         |
| 84 | Iron deficiency alters dopamine uptake and response to <scp>L</scp> â€DOPA injection in<br>Sprague–Dawley rats. Journal of Neurochemistry, 2008, 106, 205-215.   | 3.9 | 76        |
| 85 | Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. Sleep Medicine, 2008, 9, 283-289.   | 1.6 | 100       |
| 86 | Epidemiology of Restless Legs Syndrome in Korean Adults. Sleep, 2008, 31, 219-223.   | 1.1 | 119       |
| 87 | Altered Iron Metabolism in Lymphocytes from Subjects with Restless Legs Syndrome. Sleep, 2008, 31, 847-852.  | 1.1 | 35        |
| 88 | Altered expression of ironâ€management proteins in the brain microvasculature of Restless Legs<br>Syndrome. FASEB Journal, 2008, 22, 1191.5.   | 0.5 | 0         |
| 89 | Systems genetic analysis of peripheral iron parameters in the mouse. American Journal of Physiology -<br>Regulatory Integrative and Comparative Physiology, 2007, 293, R116-R124.  | 1.8 | 25        |
| 90 | Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a<br>World Association of Sleep Medicine – International Restless Legs Syndrome Study Group Consensus<br>Conference at the Max Planck Institute. Sleep Medicine, 2007, 8, 520-530. | 1.6 | 264       |

| #   | Article  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | The role of iron in restless legs syndrome. Movement Disorders, 2007, 22, S440-S448.   | 3.9 | 243       |
| 92  | Augmentation as a treatment complication of restless legs syndrome: Concept and management.<br>Movement Disorders, 2007, 22, S476-S484.                              | 3.9 | 81        |
| 93  | ls ferroportin–hepcidin signaling altered in restless legs syndrome?. Journal of the Neurological<br>Sciences, 2006, 247, 173-179.                                   | 0.6 | 73        |
| 94  | Cognitive deficits associated with restless legs syndrome (RLS). Sleep Medicine, 2006, 7, 25-30.   | 1.6 | 193       |
| 95  | Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Medicine, 2006, 7, 263-268.  | 1.6 | 85        |
| 96  | MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome.<br>Sleep Medicine, 2006, 7, 458-461.                              | 1.6 | 219       |
| 97  | Restless legs syndrome augmentation associated with tramadol. Sleep Medicine, 2006, 7, 592-593.  | 1.6 | 92        |
| 98  | The effects of dietary iron deprivation on murine circadian sleep architecture. Sleep Medicine, 2006, 7, 634-640.  | 1.6 | 46        |
| 99  | Ferritin subunits in CSF are decreased in restless legs syndrome. Translational Research, 2006, 147, 67-73.  | 2.3 | 70        |
| 100 | Segregation Analysis of Restless Legs Syndrome: Possible Evidence for a Major Gene in a Family Study<br>Using Blinded Diagnoses. Human Heredity, 2006, 62, 157-164.  | 0.8 | 35        |
| 101 | Validation of the Restless Legs Syndrome Quality of Life Questionnaire. Value in Health, 2005, 8, 157-167.   | 0.3 | 105       |
| 102 | Investigation into the correlation between sensation and leg movement in restless legs syndrome.<br>Movement Disorders, 2005, 20, 1097-1103.                         | 3.9 | 17        |
| 103 | Ferritin Levels in the Cerebrospinal Fluid and Restless Legs Syndrome: Effects of Different Clinical Phenotypes. Sleep, 2005, 28, 1069-1075.                         | 1.1 | 104       |
| 104 | Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep<br>Medicine, 2005, 6, 301-305.                                  | 1.6 | 101       |
| 105 | Response to Clinical Corners case (Sleep Medicine 6/2: 83–4): Pregnancy associated with daytime sleepiness and nighttime restlessness. Sleep Medicine, 2005, 6, 475. | 1.6 | 4         |
| 106 | An Update on the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement<br>Disorder. Sleep, 2004, 27, 560-583.                                  | 1.1 | 283       |
| 107 | Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. Journal of the Neurological Sciences, 2004, 220, 59-66.                 | 0.6 | 69        |
| 108 | An Algorithm for the Management of Restless Legs Syndrome. Mayo Clinic Proceedings, 2004, 79, 916-922.   | 3.0 | 287       |

| #   | Article   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | The treatment of restless legs syndrome with intravenous iron dextran. Sleep Medicine, 2004, 5, 231-235.  | 1.6  | 190       |
| 110 | Evaluating the quality of life of patients with restless legs syndrome. Clinical Therapeutics, 2004, 26, 925-935.   | 2.5  | 263       |
| 111 | The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Medicine, 2003, 4, 137-141. | 1.6  | 86        |
| 112 | Restless Legs Syndrome. New England Journal of Medicine, 2003, 348, 2103-2109.  | 27.0 | 300       |
| 113 | Validation of the Johns Hopkins restless legs severity scale. Sleep Medicine, 2001, 2, 239-242.   | 1.6  | 162       |
| 114 | Restless Legs Syndrome. Journal of Clinical Neurophysiology, 2001, 18, 128-147.   | 1.7  | 474       |
| 115 | CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. Movement<br>Disorders, 2001, 16, 144-149.   | 3.9  | 69        |
| 116 | Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.  | 2.9  | 209       |
| 117 | Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep<br>Medicine, 2000, 1, 11-19.   | 1.6  | 211       |
| 118 | Insight into the pathophysiology of restless legs syndrome. Journal of Neuroscience Research, 2000, 62, 623-628.  | 2.9  | 1         |
| 119 | Iron and The Restless Legs Syndrome. Sleep, 1998, 21, 381-387.  | 1.1  | 324       |
| 120 | Pergolide and Carbidopa/Levodopa Treatment of the Restless Legs Syndrome and Periodic Leg<br>Movements in Sleep in a Consecutive Series of Patients. Sleep, 1996, 19, 801-810.                                | 1.1  | 184       |
| 121 | Augmentation of the Restless Legs Syndrome With Carbidopa/Levodopa. Sleep, 1996, 19, 205-213.   | 1.1  | 424       |
| 122 | Toward a better definition of the restless legs syndrome. Movement Disorders, 1995, 10, 634-642.  | 3.9  | 1,004     |